Malaria recombinant poxviruses
    2.
    发明授权
    Malaria recombinant poxviruses 失效
    疟疾重症痘病毒

    公开(公告)号:US5766597A

    公开(公告)日:1998-06-16

    申请号:US257073

    申请日:1994-06-09

    摘要: What is described is a recombinant poxvirus, such as vaccinia or canarypox virus, containing foreign DNA from Plasmodium such as coding for at least one of CSP, PfSSP2, LSA-1, LSA-1-repeatless, MSA-1, SERA, AMA-1, Pfs25, MSA-1 N-terminal p83 and MSA-1 C-terminal gp42. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine. Preferred recombinants have attenuated virulence. In certain embodiments the vaccinia has deleted or disrupted the thymidine kinase gene, the hemorrhagic region, the A type inclusion body region, the host range gene region and, the large subunit, ribonucleotide reductase; and, contains coding sequences for CSP, PfSSP2, LSA-1-repeatless, MSA-1, SERA, AMA-1 and Pfs25. That embodiment is termed NYVAC-Pf7 and is a multicomponent, multistage vaccine since it codes for and expresses sporozoite proteins, liver stage proteins, blood stage proteins and, sexual stage proteins.

    摘要翻译: 描述的是重组痘病毒,例如痘苗或金丝雀痘病毒,其含有来自疟原虫的外来DNA,例如编码CSP,PfSSP2,LSA-1,LSA-1-无重复,MSA-1,SERA,AMA- 1,Pfs25,MSA-1 N端p83和MSA-1 C端gp42。 还描述了含有用于在接种疫苗的宿主动物中诱导免疫应答的重组痘病毒的疫苗。 优选的重组体具有减毒毒力。 在某些实施方案中,痘苗已经缺失或破坏了胸苷激酶基因,出血区域,A型包涵体区域,宿主范围基因区域和大亚基核糖核苷酸还原酶; 并且包含用于CSP,PfSSP2,LSA-1-无重复,MSA-1,SERA,AMA-1和Pfs25的编码序列。 该实施方案称为NYVAC-Pf7,并且是多组分多级疫苗,因为其编码并表达子孢子蛋白,肝阶段蛋白质,血液阶段蛋白质和性阶段蛋白质。